Brind.

ImmunityBio Leadership to Discuss Clinical and Commercial Priorities in London

1 report, 1 independent Updated Nov 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

ImmunityBio leadership is scheduled to speak at the Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference in London during Life Sciences Week 2026. The company announced that the senior leadership team will discuss its clinical and commercial priorities, including the results of the QUILT-2.005 study and efforts to expand global access to ANKTIVA.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The discussions will cover how the findings from the QUILT-2.005 study could impact the treatment of bladder cancer and where ImmunityBio sees the greatest opportunity for its immunotherapy platform. The presentations are part of a premier gathering of global investors and leaders in the pharma and biotech sectors.

From finanznachrichten.de

Who's involved

  • ImmunityBioCommercial-stage immunotherapy company presenting its clinical and commercial priorities
  • Patrick Soon-ShiongFounder and Executive Chairman of ImmunityBio

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped